Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial

Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial

Introduction Cardiac transplantation (CTx) is a life-saving operation that can improve the quality and length of a recipient’s life. Immunosuppression medication, required to prevent rejection, can result in adverse metabolic and renal effects. Clinically significant complications include metabolic...

Full description

Bibliographic Details
Main Authors: Kavitha Muthiah, Jerry R Greenfield, Nicole K Bart, Peter MacDonald, Eugene Kotlyar, Christopher S Hayward, Andrew Jabbour, Lisa Mary Raven, Christopher A Muir, Cassia Kessler Iglesias
Format: Article
Language:English
Published: BMJ Publishing Group 2023-03-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/13/3/e069641.full

Internet

https://bmjopen.bmj.com/content/13/3/e069641.full

Similar Items